A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia

Cancer

Volumn 110, Issue 5, 2007, Pages 955-964

  Kalac, Matko ^a   Quintás Cardama, Alfonso ^b   Vrhovac, Radovan ^a   Kantarjian, Hagop ^b   Verstovsek, Srdan ^b  

^a University of Zagreb   (Croatia)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Alemtuzumab; Eosinophilia; Hypereosinophilic syndrome; Imatinib; Mepolizumab; Tyrosine kinase inhibitors

Indexed keywords

ALEMTUZUMAB; ANTIMETABOLITE; BCR ABL PROTEIN; CHLORAMBUCIL; CLADRIBINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; INTERLEUKIN 5; MEPOLIZUMAB; METHOTREXATE; MIDOSTAURIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROTEIN FIP1L1 PDGFRA; PROTEIN FIP1L1 PDGFRA T674; PROTEIN SUBUNIT; PROTEIN TYROSINE KINASE INHIBITOR; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; EOSINOPHILIA; GENETIC LINKAGE; HUMAN; HYPEREOSINOPHILIC SYNDROME; MOLECULAR DYNAMICS; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLONE CELLS; EOSINOPHILIA; HUMANS; HYPEREOSINOPHILIC SYNDROME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 34548177003     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22920     Document Type: Review

References (111)

1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
3. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.
4. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52:1-22.
5. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982;97:78-92.
6. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol. 2004;77:82-85.
7. Tefferi A, Elliott MA, Pardanani A. Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin Proc. 2006;81:553-563.
8. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol. 2005;114:7-25.
9. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA(+) chronic eosinophilic leukemias. Leukemia. 2004;18:734-742.
10. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol. 2003;122:173-179.
11. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651-1657.
12. Needleman SW, Mane SM, Gutheil JC, Kapil V, Heyman MR, Testa JR. Hypereosinophilic syndrome with evolution to myeloproliferative disorder: temporal relationship to loss of Y chromosome and c-N-ras activation. Hematol Pathol. 1990;4:149-155.
13. Higuchi W, Koike T, Ihizumi T, Shibata A. Hypereosinophilic syndrome terminating in acute myelogenous leukemia. Acta Haematol. 1993;90:165-166.
14. Cogan E, Schandene L, Crusiaux A, Cochaux P Velu T, Goldman M. Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535-538.
15. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112-1120.
16. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109:540-548.
17. Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today. 1991;12:256-257.
18. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol. 2005;114:52-60.
19. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006;133:468-492.
20. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Il. Clinical manifestations. Blood. 1981;58:1021-1026.
21. Marshall GM, White L. Effective therapy for a severe case of the idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. 1989;11:178-183.
22. Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol. 1992;14:348-351.
23. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia. 1997;11:1386-1390.
24. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994;121:648-653.
25. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826-2827.
26. Ault P Cortes J, Roller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
27. Zielinski RM, Lawrence WD. Interferon-alpha for the hypereosinophilic syndrome. Ann Intern Med. 1990;113:716-718.
28. Fruehauf S, Fiehn C, Haas R, Doehner H, Hunstein W. Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy. Acta Haematol. 1993;89:91-93.
29. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa. J Allergy Clin Immunol. 1994;94:1318-1326.
30. Bockenstedt PL, Santinga JT, Bolling SF. Alpha-interferon treatment for idiopathic hypereosinophilic syndrome. Am J Hematol. 1994;45:248-251.
31. Papo T, Piette JC, Hermine O. Treatment of the hypereosinophilic syndrome with interferon-alpha. Ann Intern Med. 1995;123:155-156.
32. Schandene L, Roufosse F, de Lavareille A, et al. Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia. Blood. 2000;96:4285-4292.
33. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol. 1991;62:230-231.
34. Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics. 1997;99:630-633.
35. Lindscheid KR, Zabel M. Hypereosinophilia syndrome with cutaneous manifestations, "burning hand" syndrome and increased immunoglobulin levels. Treatment with a combination of DADPS and disodium cromoglycate. Z Hautkr. 1988;63:338-343.
36. Gehrke D, Herzum M, Schonian U, et al. Eosinophilic endomyocarditis post partum or pregnancy-related cardiomyopathy. Herz. 1994;19:176-181.
37. Hagendorff A, Hummelgen M, Omran H, et al. Loffler fibroblastic endocarditis in the thrombotic stages in isolated right ventricular tissue eosinophilia. Z Kardiol. 1998;87:293-299.
38. Archimbaud E, Guyotat D, Guillaume C, Godard J. Fiere D. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol. 1988;27:302-303.
39. Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol. 1996;51:164-165.
40. Sadoun A, Lacotte L, Delwail V, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant. 1997;19:741-743.
41. Juvonen E, Volin L, Koponen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant. 2002;29:457-458.
42. Cooper MA, Akard LP, Thompson JM, Dugan MJ, Jansen J. Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. Am J Hematol. 2005;78:33-36.
43. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119:131-134.
44. Halaburda K, Prejzner W, Szatkowski D, Limon J, Hellmann A. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant. 2006;38:319-320.
45. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
46. De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia. 2006;20:200-205.
47. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952.
48. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493-502.
49. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
50. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001;3:9-9.
51. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
52. Nolasco I, Carvalho S, Parreira A, et al. Rapid and complete response to imatinib mesylate (STI-571) in a patient with idiopathic hypereosinophilia. [abstract]. Blood. 2002;100:346b.
53. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. [review]. Leuk Res. 2004;28(suppl 1):S47-S52.
54. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA. 2003;100:7830-7835.
55. Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003;27:883-885.
56. Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res. 2006;30:1201-1205.
57. Tefferi A, Pardanani A, Li CY. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? Blood. 2003;102:3073-3074.
58. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
59. Cortes J, Ault P Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714-4716.
60. Cervetti G, Galimberti S, Carulli G, Petrini M. Imatinib therapy in hypereosinophilic syndrome: a case of molecular remission. Leuk Res. 2005;29:1097-1098.
61. Ascione L, De Michele M, Accadia M, Spadaro P, Rumolo S, Tuccillo B. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor. Eur J Echocardiogr. 2004;5:386-390.
62. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol. 2004;11:51-57.
63. Pardanani A, Ketterling RP, Li CY, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006;30:965-970.
64. Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med. 2004;351:2134-2135.
65. Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood. 2003;102:3456-3457.
66. Cools J, Maertens C, Marynen P. Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist Updat. 2005;8:119-129.
67. Gupta R, Knight CL, Bain BJ. Receptor tyrosine kinase mutations in myeloid neoplasms. Br J Haematol. 2002;117:489-508.
68. Tauchi T, Ohyashiki K. The second generation of BCR-ABL tyrosine kinase inhibitors. Int J Hematol. 2006;83:294-300.
69. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332-2338.
70. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005;1754:3-13.
71. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
72. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11:4941-4947.
73. Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005;104:1230-1236.
74. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005;106:3206-3213.
75. Verstovsek S, Giles FJ, Quintas-Cardama A, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006;30:1499-1505.
76. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
77. O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell. 2005;7:117-119.
78. von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J. The FIP1L1-PDGFRA T6741 mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood. 2006;107:4970-4971.
79. Zhang Z, Meier KE. New assignments for multitasking signal transduction inhibitors. Mol Pharmacol. 2006;69:1510-1512.
80. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473-481.
81. Deng Q, Mitsiades N, Negri J, et al. Dasatinib (BMS354825): a multi-targeted kinase inhibitor with activity against multiple myeloma [ASH Annual Meeting Abstracts]. Blood. 2005;106. Abstract 1571.
82. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
83. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
84. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94:614-619.
85. Siu LL, Awada A, Takimoto CH, et al. Phase 1 of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12:144-151.
86. Strumberg D, Richly H, Hilger RA, et al. Phase 1 clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972.
87. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92:1855-1861.
88. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23:329-336.
89. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib resistant FIP1L1-PDGFRalpha T6741 mutant. Blood. 2006;108:1374-1376.
90. Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 1992;52:5353-5358.
91. Fabbro D, Buchdunger E, Wood J, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther. 1999;82:293-301.
92. Fabbro D, Ruetz S, Bodis S, et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15:17-28.
93. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol. 2001;19:1485-1492.
94. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433-443.
95. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60.
96. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3:459-469.
97. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004,103:2879-2891.
98. le Coutre P, Hochhaus A, Heim D, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosiniphilic syndrome (HES) [ASH Annual Meeting Abstracts]. Blood. 2006;108. Abstract 4912.
99. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101-3109.
100. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther. 1999;291:1060-1067.
101. Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999;11:1935-1943.
102. Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49:779-790.
103. Leckie MJ, Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144-2148.
104. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111:714-719.
105. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 2003,115:587-589.
106. Plotz SG, Simon HU, Darsow U, et al. Use of anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334-2339.
107. Rothenberg ME, Gleich GJ, Roufosse FE, Rosenwasser LJ, Weller PF. Steroid-sparing effects of anti-IL-5 monoclonal antibody (mepolizumab) therapy in patients with HES: a multicenter, randomized, double-blind, placebo-controlled trial [ASH Annual Meeting Abstracts]. Blood. 2006;108. Abstract 373.
108. Eisner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood. 1996,88:4684-4693.
109. Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol. 2004;124:558-559.
110. Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol. 2004,127:477-477.
111. Quintas-Cardama A, Tefferi A, Cortes J, et al. Alemtuzumab (CAMPATH-1H™) is effective therapy for hypereosinophilic syndrome (HES) [ASH Annual Meeting Abstracts]. Blood. 2006;108. Abstract 4902.